Characteristics of metastatic lung cancer patients on osimertinib therapy in Bangladesh

Eighty patients with metastatic lung cancer receiving osimertinib therapy were included in this descriptive cross-sectional study. This study covered patients with lung cancer metastases who were receiving osimertinib, regardless of age and sex. Results: According to the findings, the patients' mean (±SD) age was 60.95 ±13.98 years. Patients who were between the ages of 55 and 75 had the highest rate of metastases. Under the age of 55, brain metastases (27%) were more common in both sexes (16.2%). While spinal metastasis was more frequent in female patients (8.1%), skin metastasis was more common in male patients (16.2%). Skin metastases were most frequently observed in patients aged 55 to 65 (10.8%), followed by those aged 25 to 45 (5.4%). Conclusions: Mid-age male patients have been observed to have more cases of brain metastases and metastatic lung cancer. The findings are not conclusive due to the small sample size but suggest that the site of metastasis varied according to the patient's demographic characteristics. Further research on this topic is recommended to yield evidence for practitioners and policymakers.

According to the findings, the patients' mean (±SD) age was 60.95 ±13.98 years. Patients who were between the ages of 55 and 75 had the highest rate of metastases. Under the age of 55, brain metastases (27%) were more common in both sexes (16.2%). While spinal metastasis was more frequent in female patients (8.1%), skin metastasis was more common in male patients (16.2%). Skin metastases were most frequently observed in patients aged 55 to 65 (10.8%), followed by those aged 25 to 45 (5.4%).

Mid-age male patients have been observed to have more cases of brain metastases and metastatic lung cancer. The findings are not conclusive due to the small sample size but suggest that the site of metastasis varied according to the patient's demographic characteristics. Further research on this topic is recommended to yield evidence for practitioners and policymakers.